[{"orgOrder":0,"company":"GEDiCube","sponsor":"Renovaro Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2023","type":"Merger","leadProduct":"Dendritic Cell Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"GEDiCube","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GEDiCube \/ Renovaro Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"GEDiCube \/ Renovaro Biosciences"}]

Find Clinical Drug Pipeline Developments & Deals by GEDiCube

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms to accelerate Renovaro’s development of potential new therapies, including RENB-DC-11, a dendritic cel...

                          Product Name : RENB-DC-11

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          September 29, 2023

                          Lead Product(s) : Dendritic Cell Vaccine

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Renovaro Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank